Colossal Secures $200M to Accelerate De-Extinction and Genomic Innovation

Series C funding boosts Colossal’s valuation to $10.2B, fueling species revival and conservation genetics projects.

BY David Bloom

Colossal Biosciences has secured $200 million in Series C funding led by TWG Global, elevating the Texas-based company’s valuation to $10.2 billion and earning it “decacorn” status. The investment will scale CRISPR and synthetic biology programs aimed at reviving species such as the woolly mammoth, dodo, and thylacine, while advancing technologies like artificial wombs and genomic preservation platforms. The funding also supports team growth and expands Colossal’s species portfolio, reinforcing its position at the forefront of de-extinction and conservation genetics. These capabilities extend beyond species revival to protecting biodiversity and restoring ecosystems. Among its high-profile initiatives is the Colossal Dire Wolf de-extinction project, which applies advanced genomics to bring back one of North America’s most iconic keystone species.

Read the full feature in Forbes.